

The Crutchfield-Brownstone-Lebwohl Biologic Medication Quick Reference Chart for Psoriasis and Atopic Dermatitis (& H.S.)

Brand Name	Generic Name	Ages	Loading Dose	Maintenance Dose	Target					
					TNF	IL-4	IL-12	IL-13	IL-17	IL-23
Enbrel*	Etanercept	PsA 18 yrs +	50 mg SQ Twice Weekly for 12 wks	50 mg SQ q wk	√					
		PsO 4 yrs +	PEDS: 0.8 mg/kg q wk (max-dose 50 mg q wk)							
Humira*	Adalimumab	18 yrs +	80 mg SQ on Day 1 and then 40 mg SQ on Day 8	40 mg SQ q2 wks	√					
Humira HS (Hidradenitis Suppurativa)	Adalimumab	12 years and older	160mg SQ Day 1, 80mg SQ Day 15 or 80mg Day 1, 80mg Day 2, 80mg SQ Day 15	Then 40 mg qW starting Day 29 or 80mg SQ q 2 weeks	√					
Remicade*	Infliximab	18 yrs +	5 mg/kg IV wk 0, 2, and 6	5 mg/kg IV q8 wks	√					
Cimzia*	Certolizumab Pegol	PsO / PsA 18 yrs +	>90 kg: No Loading Dose	400 mg SQ q2 wks	√					
			<90 kg: 400 mg SQ at wk 0, 2 and 4	200 mg SQ q2 wks						
Stelara*	Ustekinumab	PsO 6 yrs + PsA 18 yrs +	<100 kg: 45 mg SQ at wk 0 and 4	45 mg SQ q12 wks			√			√
			>100 kg: 90 mg SQ at wk 0 and 4	90 mg SQ q12 wks						
			PEDS: Weight-based dosing recommended at initial dose, 4 weeks later, then q12 weeks. Less than 60 kg = 0.75 mg/kg 60 kg to 100 kg = 45 mg Greater than 100 kg = 90 mg							
Cosentyx*	Secukinumab	PsA 2 yrs + PsO 6 yrs +	300 mg SQ at wk 0, 1, 2, 3, and 4	300 mg SQ q4 wks						√
			PEDS: Dosage based on body weight and administered by SQ at wks 0, 1, 2, 3, and 4 and q4 wks Less than 50 kg = 75 mg Greater than or equal to 50 kg = 150 mg							
Taltz*	Izекizumab	PsA 18 yrs + PsO 6 yrs +	160 mg at wk0, then 80 mg at wk 2, 4, 6, 8, 10, and 12	80 mg SQ q4 wks						√
			PEDS: Greater than 50 kg = 160 mg at wk0 then 80 mg q4 wks 25 to 50 kg = 80 mg at wk0 then 40 mg q4 wks Less than 25 kg = 40 mg at wk0 then 20 mg q4 wks							
Siliq	Brodalumab	18 yrs +	210 mg SQ at wk 0, 1, and 2	210 mg SQ q2 wks						√
Tremfya*	Guselkumab	PsO / PsA 18 yrs +	100 mg SQ at wk 0 and 4	100 mg SQ q8 wks						√
Illumya	Tildrakisumab	18 yrs +	100 mg SQ at wk 0 and 4	100 mg SQ q12 wks						√
Skyrizi*	Risankizumab-rzaa	PsO / PsA 18 yrs +	150 mg SQ at wk 0 and 4	150 mg SQ q12 wks						√
Dupixent (Atopic Dermatitis)	Dupilumab	6 months +	600 mg (Adult Dosing)	300 mg SQ q2 wk (Adult Dosing)			√		√	
			PEDS: 6 months to 5 years old: 5 kg to <15 kg: Inital 200 mg subQ wk 0, then 200 mg subQ every 4 wks 15 kg to 30 kg: inital: 300mg subQ wk 0, then 300 mg subQ every 4 weeks PEDS 6-17 years: 15 to less than 30 kg = 600 mg at wk0 then 300mg q4 wks 30 to less than 60 kg = 400 mg at wk 0 then 200 mg q2 wks 60 kg or more = 600 mg at wk0 then 300 mg q2 wks							
Adbry (Atopic Dermatitis)	Tralokinumab	18 yrs +	600 mg	Then 40 mg qW starting Day 29					√	

SQ = subcutaneous, q = every, W/wk = weeks, PEDS = pediatric dosing

*FDA approved to treat both psoriasis and psoriatic arthritis

DISCLAIMER: The dosages seen in this chart were obtained from the respective FDA approved package inserts.

This chart is for reference only and not to be substituted for clinical judgement.

The authors are not responsible for treatment decisions or outcomes based on information in this chart.

[This chart can be downloaded at: crutchfielddermatology.com/biologicmedicationinformation/](http://crutchfielddermatology.com/biologicmedicationinformation/)